Susquehanna International Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-15,357
Closed -$93K 11346
2019
Q4
$93K Sell
15,357
-57,180
-79% -$331K ﹤0.01% 9168
2019
Q3
$261K Sell
72,537
-67,247
-48% -$259K ﹤0.01% 8607
2019
Q2
$375K Buy
+139,784
New +$413K ﹤0.01% 7872
2019
Q1
Sell
-98,696
Closed -$242K 10360
2018
Q4
$156K Buy
98,696
+77,456
+365% +$219K ﹤0.01% 7954
2018
Q3
$78K Sell
21,240
-112,801
-84% -$336K ﹤0.01% 8696
2018
Q2
$379K Buy
134,041
+32,141
+32% +$109K ﹤0.01% 7379
2018
Q1
$378K Sell
101,900
-104,834
-51% -$343K ﹤0.01% 7202
2017
Q4
$595K Buy
206,734
+191,896
+1,293% +$697K ﹤0.01% 6307
2017
Q3
$67K Sell
14,838
-23,711
-62% -$105K ﹤0.01% 8475
2017
Q2
$177K Sell
38,549
-171,165
-82% -$688K ﹤0.01% 8381
2017
Q1
$883K Buy
209,714
+83,886
+67% +$348K ﹤0.01% 5389
2016
Q4
$520K Buy
125,828
+103,271
+458% +$549K ﹤0.01% 6899
2016
Q3
$183K Buy
+22,557
New +$192K ﹤0.01% 7645
2016
Q2
Sell
-122,620
Closed -$1.05M 9685
2016
Q1
$947K Sell
122,620
-70,243
-36% -$514K ﹤0.01% 5202
2015
Q4
$2.08M Sell
192,863
-445,125
-70% -$4.05M ﹤0.01% 3958
2015
Q3
$4.41M Sell
637,988
-3,813
-0.6% -$31.1K ﹤0.01% 2860
2015
Q2
$5.69M Sell
641,801
-50,976
-7% -$482K ﹤0.01% 2718
2015
Q1
$6.83M Buy
692,777
+572,687
+477% +$7.15M ﹤0.01% 2310
2014
Q4
$1.47M Sell
120,090
-40,524
-25% -$495K ﹤0.01% 5078
2014
Q3
$1.6M Buy
160,614
+13,522
+9% +$126K ﹤0.01% 5020
2014
Q2
$1.11M Sell
147,092
-248,175
-63% -$990K ﹤0.01% 5818
2014
Q1
$1.3M Buy
395,267
+149,460
+61% +$523K ﹤0.01% 5055
2013
Q4
$816K Sell
245,807
-521,453
-68% -$1.51M ﹤0.01% 5849
2013
Q3
$2.32M Buy
767,260
+3,530
+0.5% +$24.2K ﹤0.01% 3868
2013
Q2
$6.25M Buy
+763,730
New +$5.83M ﹤0.01% 2338

Susquehanna International Group's ACHN Position: Q1 2020 in Review

Susquehanna International Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 15,357 shares — an estimated $93K sold.

Susquehanna International Group first reported a position in ACHN in Q2 2013 and held it in 25 quarters. The position peaked at $6.83M in Q1 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • Susquehanna International Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Susquehanna International Group sold 15,357 Achillion Pharmaceuticals shares in Q1 2020, an estimated $93K.
  • Susquehanna International Group first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Susquehanna International Group's Achillion Pharmaceuticals position peaked at $6.83M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.